Introduction {#s1}
============

Thyrotropin releasing hormone (TRH; Glp-His-Pro-NH~2~) is a small peptide expressed mainly in the brain, secreted by neurons. TRH interacts with plasma membrane G-protein-coupled receptors; one TRH receptor (TRH-R1) is detected in humans, whereas an additional one (TRH-R2) in rodents ([@B201]) and a total of three in teleosts and frogs ([@B16]; [@B180]). In mammals, TRH-R1 and TRH-R2 arise from different genes ([@B201]); the maps of their brain expression do not coincide ([@B74]); they possess distinct ligand-independent activities, with TRH-R2 showing a stronger constitutive activity ([@B226]). These distinct characteristics and the differential behaviors of KO mice for each receptor ([@B165]; [@B250]; [@B202]) suggest that each type of receptor fulfills distinct functions in response to TRH. However, data in mice indicate that central TRH effects may depend mainly on TRH-R1 expression ([@B214]).

The best-known function of TRH is the control of the hypothalamus--pituitary--thyroid (HPT) axis; TRH is synthesized by processing of a protein precursor in neurons of the paraventricular nucleus of the hypothalamus (PVN) that project their terminal boutons into the median eminence (hypophysiotropic neurons). Once released into the extracellular space TRH diffuses into the hypothalamic-pituitary portal vessels from where it controls secretion of thyrotropin (TSH) from the anterior pituitary. In turn, TSH controls the synthesis and secretion of thyroid hormones (TH) in the thyroid. This link adjusts TH secretion according to energy balance information, which is integrated by the hypophysiotropic PVN TRH neurons. TRH may also control prolactin secretion from the anterior pituitary ([@B124]; [@B90]), although hypophysiotropic PVN TRH neurons regulating prolactin may differ from those controlling TSH secretion ([@B175]).

Various additional hypothalamic and extrahypothalamic neuronal populations express *Trh* ([@B115]; [@B191]; [@B70]; [@B74]), but their physiological role is not well understood. Soon after the discovery of extrahypothalamic TRH, several studies revealed central pharmacological effects of TRH that were independent of HPT axis control in laboratory animals, including increased locomotion, arousal, improvement of depression-like behaviors, reduction of epileptic seizures, and neuroprotection ([@B79]; [@B61]; [@B41]; [@B57]). These observations led to attempts to use TRH in therapeutic contexts, for example in some neurodegenerative diseases ([@B61]; [@B41]; [@B57]). Moreover, TRH is also present in selected loci outside the central nervous system whose importance is still poorly appreciated.

Early evidence that the half-life of TRH in rodent blood or in tissue extracts is 3--5 min ([@B167]; [@B160]; [@B211]), and that TRH pharmacological effects are of short duration led to the synthesis of TRH analogues with improved stability, agonist potency and/or brain accessibility ([@B79]; [@B61]; [@B41]; [@B57]). Other efforts were directed to elucidate the mechanism contributing to the rapid extracellular disappearance of TRH. TRH can be removed from the brain extracellular space by transport into brain cells; nevertheless, this event has a small V~max~ and may have a very limited quantitative importance ([@B25]). The molecular entity that contributes to this transport has not been characterized; it may reflect TRH-R mediated endocytosis ([@B5]), or the action of a TRH transporter ([@B7]).

Alternatively, TRH may be hydrolyzed by peptidases. Pyroglutamyl peptidase I (PPI; EC 3.4.19.3) is a soluble cysteine aminopeptidase with a wide specificity, that hydrolyses almost any Glp-X peptide, except if X is a proline ([@B6]). This enzyme is present in all life kingdoms, and found in many tissues, including brain. Although PPI hydrolyses TRH *in vitro* ([@B135]; [@B141]; [@B29]), the only evidence that it contributes to TRH turnover *in situ* is that an inhibitor of PPI (and PE) enhances TRH levels and release in primary cultures of hypothalamic cells ([@B51]). Since PPI action is probably restricted to the cytoplasm, it may contribute to the intracellular turnover of TRH leaking from intracellular granules, but its subcellular localization is not compatible with a post-secretory role. In support of this idea, the specific inhibition of PPI activity in brain slices does not change TRH release and the intraperitoneal injection of a specific inhibitor of PPI that inhibits brain PPI activity does not change brain TRH levels ([@B26]). Furthermore, inhibition of enzyme activity does not protect TRH from degradation in rat serum ([@B58]).

Prolyl endopeptidase (PE; EC 3.4.21.26) is a serine endopeptidase with a wide specificity; it hydrolyses internal Pro-X peptide bonds, except if X is a proline. This enzyme is soluble, present in all life kingdoms, and many tissues, including the mammalian brain, albeit a membrane-bound isoform has also been identified. PE hydrolyzes the Pro-NH~2~ bond of TRH *in vitro* ([@B228]; [@B141]; [@B29]; [@B212]). PE role in TRH turnover *in vivo* is controversial; inhibition of PE enhances TRH levels and release in primary cultures of hypothalamic cells ([@B51]), the intraperitoneal injection of a PE inhibitor enhances TRH concentration in the cerebral cortex ([@B14]), and PE or a similar enzyme degrades TRH in rabbit seminal plasma ([@B196]). However, other experiments showed that PE inhibition in brain slices does not change TRH release into the medium and that the intraperitoneal injection of a specific inhibitor of PE does not change brain TRH levels *in vivo* ([@B26]). Furthermore, the intraseptal injection of a PE inhibitor does not change the effect of TRH on time of arousal from ethanol-induced narcosis in rats ([@B113]). Since PE regulates inositol polyphosphate phosphatase activities ([@B229]), the effect of PE inhibition on TRH levels may result from an alteration of the intracellular turnover of the secretory granules that contain TRH. Likewise, inhibition of PE does not protect TRH from degradation in rat serum ([@B58]). Thus, in general, PE may not control the extracellular turnover of TRH.

Another peptidase that may hydrolyze TRH is prolyl carboxypeptidase (PCP; EC 3.4.16.2) ([@B86]), but there is no evidence that PCP coincides with TRH or alters TRH biological actions *in vivo*. Therefore, the quantitative importance of the previously described mechanisms of inactivation of TRH may be very limited *in vivo*, in particular for its extracellular inactivation, due in most cases to incompatible subcellular localizations of peptide and enzymes ([@B29]). In sum, contrary to what is sometimes mentioned in the literature, neither uptake nor soluble peptidases constitute relevant mechanisms for the extracellular inactivation of TRH.

The discovery of the thyrotropin-releasing hormone-degrading ectoenzyme (TRH-DE; EC 3.4.19.6) stems from the identification of an enzymatic activity that hydrolyses the Glp--His bond of TRH, initially in serum and called thyroliberinase, to underpin its narrow specificity ([@B9]), and later in brain ([@B60]). The most striking property of this pyroglutamyl peptidase is a very narrow specificity ([@B112]; [@B227]; [@B49]; [@B59]; [@B72]), a compelling argument in favor of looking at this peptidase as a therapeutic target, for example when enhancement of TRH action may be beneficial. TRH-DE was initially named pyroglutamyl peptidase II (PPII), to stress its clear biochemical difference with PPI; in contrast to PPI, TRH-DE/PPII is a metallopeptidase ([@B40]). A review describing the major biochemical characteristics of TRH-DE was previously published ([@B177]).

In the next sections, we briefly review the structure and proposed physiological roles of TRH-DE, focusing on recent advances, and we identify major challenges to translate this knowledge to clinical applications. Although the biochemical, topological and functional properties of the enzyme strongly argue in favor of its implication in the extracellular inactivation of TRH, its role may vary with cellular context, and might extend beyond hydrolysis of TRH. Contexts in which an intervention on TRH-DE may have therapeutic potential are delineated, and limitations are identified.

*Trhde* Gene, Transcripts, Protein Structure, Isoforms and Specificity {#s2}
======================================================================

The sequence and genomic locus of the *Trhde* gene (we use the rodent abbreviations for gene names throughout the review) was initially described in humans ([@B188]); there is only one gene localized on chromosome 12. In mammals, the *Trhde* gene is adjacent to the tryptophan hydroxylase 2 gene (<https://www.ensembl.org>). In mouse, the gene localizes to chromosome 10 (<http://www.informatics.jax.org/marker/MGI:2384311>) while in rats, to chromosome 7. *Trhde* gene sequences and enzymatic activities have been detected in mammals, including activity in human serum and cerebrospinal fluid ([@B159]; [@B20]; [@B29]). The gene is also detected in other vertebrate classes ([@B188]; [@B24]). TRH-DE is not an essential gene in mice as TRH-DE KO animals are healthy, reproduce normally and their metabolic parameters are normal when bred in standard conditions ([@B210]).

*Trhde* transcription initiation sites have not been formally mapped. In mouse, three transcription start sites have been proposed (<http://www.informatics.jax.org/marker/MGI:2384311>); two are conserved in rat for which various transcripts differing widely in size have been detected ([@B186]). Apart from alternative transcription start sites, there is little information about the mechanisms that lead to transcript diversity, except for a potential alternative splicing event in rats at exon 14-intron 14 boundary that leads to a truncated TRH-DE isoform ([@B31]). In mice three alternative splicing events may generate various TRH-DE isoforms (<http://www.informatics.jax.org/>). Bioinformatic approaches suggest that in mice response elements for multiple transcription factors exist along the 2 Kb region upstream from the most upstream of the predicted transcriptional start sites ([**Figure 1**](#f1){ref-type="fig"}). However, promoter structure and genomic regulatory elements have not been experimentally mapped.

![A map of candidates for transcriptional regulation of *Trhde* expression predicted by bioinformatic analysis. Transcription factor binding sites were identified 2 kb upstream of the most upstream of the 3 predicted transcriptional start sites (TSSR99301) of the mouse with PROMO ([@B130]; [@B52]). This site is conserved in rats. AR, androgen receptor; Crx, Cone-rod homeobox protein; GR, glucocorticoid receptor; NF-kappaB, nuclear factor kappa-light-chain-enhancer of activated B cells; POU2F1, POU domain, class 2, transcription factor 1; Sp1, specificity protein 1.](fphar-11-00640-g001){#f1}

Another transcript derived from the human *Trhde* locus is *Trhde* antisense RNA 1 (*Trhde-as1*) (<https://www.ncbi.nlm.nih.gov/nuccore/NR_026837>). This long non-coding RNA is found in the cytoplasm and binds directly to miR-103 in samples of human lung, inhibiting parameters of human lung cancer progression ([@B252]). Individuals challenged with an injection of LPS show a significant drop of *Trhde-as1* expression in adipose tissue samples ([@B55]). The relevance of *Trhde-as1* expression for *Trhde* function is unknown.

The purification and cloning of the rat brain/pituitary isoform revealed that TRH-DE is 1,025 amino acids long (1,024 in human) ([@B13]; [@B186]). TRH-DE is a member of the M1 family of zinc-aminopeptidases, a family of 12 members (in humans) that includes aminopeptidases that have a wider specificity than TRH-DE, including aminopeptidase N (the closest relative of TRH-DE), which preferentially hydrolyses neutral aminoacids from the N-terminus ([@B197]). Although TRH-DE 3D structure is still unknown, analogy with other members of the family suggests it is a type II cell surface peptidase with a small intracellular domain, a single transmembrane domain, and a large extracellular part with a flexible stem followed by a catalytic domain, and an additional domain separated by a flexible loop ([@B24]). Topology of the domains is consistent with biochemical evidence that demonstrated TRH-DE is an ectoenzyme ([@B27]), making it a prime candidate for primary hydrolysis of TRH in the extracellular space.

A large set of TRH derivatives has been tested to define TRH-DE specificity; TRH analogues modified on the C- or N-terminal residues are poor substrates of TRH-DE ([@B112]; [@B227]; [@B72]; [@B96]). For example, gonadotropin-releasing hormone (GnRH), a decapeptide with a N-terminal Glp-His is not a substrate of TRH-DE ([@B140]; [@B49]; [@B59]). Substitution of the histidyl residue of TRH by a series of amino acids influences the ability of porcine TRH-DE to catalyze the hydrolysis of the Glp-X bond in TRH-like peptides; thus, TRH-like peptides substituted with Gly, Asn, Gln, Trp, Glu, Asp, Pro or Cys are not substrates of TRH-DE, while low turnover rates are observed with Ala, Ser, Thr, Ile, Leu, Val. In contrast, TRH-like peptides substituted with Tyr or Phe have turnover rates approaching that of TRH ([@B96]). This agrees with evidence that Glp-Phe-Pro-NH~2~ is a substrate of bovine brain TRH-DE ([@B95]; [@B59]). The structural determinants of TRH-DE narrow specificity have been partially clarified; two amino-acid substitutions in the catalytic domain are critical and form a conserved signature that distinguishes it from other M1 family members ([@B24]).

One of the two TRH-like peptides that are relatively good substrates of the enzyme *in vitro*, Gln-Phe-Pro-NH~2~, has been detected in peripheral organs including pancreas and thyroid gland ([@B100]; [@B63]; [@B110]). Although it was initially suggested that TRH-like peptides, other than TRH, were not detectable in brain ([@B171]; [@B172]), it was later shown that, among other, Gln-Tyr-Pro-NH~2~, and Gln-Phe-Pro-NH~2~ are present in brain ([@B151]; [@B152]). To our knowledge, although these peptides are likely the product of posttranslational processing of precursor peptides ([@B119]), the precursors are still unknown. However, they may act as intercellular messengers, including in the brain, since their concentrations can vary rapidly in response to some stimuli, suggesting changes in synthesis and/or release ([@B149]; [@B153]), and there is direct evidence that a peptide similar to Gln-Phe-Pro-NH~2~ can be released into hypothalamic extracellular space *in vitro* ([@B121]). *Bona fide* receptors for Gln-Phe-Pro-NH~2~ and Gln-Tyr-Pro-NH~2~ have not been detected; they are weak agonists of TRH receptors ([@B76]).

Information about TRH-DE biosynthesis, transport and turnover is scant. The membrane isoform is a N-glycosylated protein; within its large extracellular domain, 12 putative N-glycosylation sites are found ([@B186]). In its native form, TRH-DE can be partially deglycosylated (by about 50%) without affecting its activity ([@B13]). The relevance of remaining glycosyl residues is not yet known. N-linked protein glycosylation starts in the endoplasmic reticulum and is a conserved process in eukaryotic cells. The subsequent details of processing that occur in Golgi compartments, according to protein-, cell- and species-specific clues ([@B1]), have not been described for TRH-DE. Thyroliberinase, the soluble isoform secreted into blood, may be a product of alternative splicing or proteolysis ([@B187]). A membrane-bound truncated TRH-DE (TRH-DE\*) is detected in many tissues, formed probably through an alternative splicing event; TRH-DE\* does not hydrolyze TRH but it inhibits TRH-DE activity when it dimerizes with the full-length TRH-DE ([@B31]). In line with these results, correlative evidence suggests that the tissue-specific pattern of TRH-DE activity is defined in part by the *Trhde*/*Trhde*\* expression ratio ([@B31]). Finally, little is known about TRH-DE interactions with other proteins. TRH-DE\* may interact physically with Akt1 in mesenchymal-derived soft tissue sarcoma (STS) cell lines ([@B251]) but an interpretation of the physiological relevance of this interaction awaits resolution.

Specific Inhibitors of TRH-DE {#s3}
=============================

To investigate the biological functions of TRH-DE, TRH-DE inhibitors have been synthesized. Protease inhibitors frequently include structural features that enable their interaction with the active site of the enzyme ([@B39]; [@B94]). TRH-DE is weakly inhibited by the products of hydrolysis of TRH, Glp and His-Pro-NH~2~; combination of these molecules with zinc-binding groups results in poor TRH-DE inhibitors ([@B11]). In general, TRH derivatives with modifications to the C- or N-terminal residues of TRH do not inhibit TRH-DE activity ([@B112]; [@B227]; [@B49]; [@B59]; [@B96]). However, GnRH, a Glp-His peptide C-terminally extended with hydrophobic residues does inhibit TRH-DE activity ([@B140]; [@B49]; [@B59]). Furthermore, some analogues modified on the histidine residue have also shown some potential. Thus, the first specific inhibitor described was N-\[1-carboxy-2-phenylethyl\]N-imidazole benzyl histidyl-β-naphthylamide (CPHNA). With a Ki of 8 µM, CPHNA has no effect on TRH receptors and does not inhibit PE activity ([@B28]).

The systematic screening of a directed peptide library led to the finding that Glp-Asn-Pro-7-amido-4-methyl coumarin (Glp-Asn-Pro-AMC) has a Ki of 0.97 µM, making this peptide a relatively potent reversible TRH-DE inhibitor ([@B96]). Improved potency was achieved by extension of Glp-Asn-ProNH~2~ with hydrophobic amino acids at the C-terminus. Thus, Glp-Asn-Pro-Tyr-Trp-Trp-AMC displays a Ki of 1 nM, which makes it the most potent competitive TRH-DE inhibitor described to date. Unfortunately, the *in vivo* potency of this peptide is poor ([@B97])

Another potent synthetic inhibitor of TRH-DE is the phosphinic analogue of TRH, GlpΨ\[P(O)(OH)\]HisProNH2 (Ψ-TRH) with a Ki of 170 nM, in which the scissile peptide bond of TRH has been replaced by the chemically stable phosphinic bond ([@B127]).

Finally, a natural TRH-DE inhibitor named *Hermodice carunculata* protease inhibitor (HcPI) was isolated from the marine annelide *H. carunculata*. HcPI inhibits rat TRH-DE (a brain membrane extract with 7.5 mg protein/ml) with an IC~50~ of 4.8 μg/ml ([@B146]). It is a small hydrophilic molecule very specific for TRH-DE, since it is at least 100 fold less potent at inhibiting the activity of the nearest homologue in the M1 family, aminopeptidase N ([@B37]), and it is brain permeant ([@B146]). HcPI structure is still unknown; solving it may lead to new tools.

TRH Analogues Resistant to Hydrolysis {#s4}
=====================================

TRH is a poor drug candidate. Although TRH is stable in the gastrointestinal tract, it has low intestinal permeability ([@B242]). The intranasal route of delivery presents a possible alternative route to access the brain ([@B224]; [@B246]). Furthermore, TRH has also a short plasma half-life, being rapidly hydrolyzed by peptidases ([@B167]; [@B160]; [@B211]), and its cerebral absorption is low ([@B34]). Finally, TRH has extensive neuroendocrine, central and autonomic/cardiac effects that may limit its therapeutic use (Gary et al., 2013; [@B101]; [@B90]).

Thus, TRH analogues have been developed to increase stability, delivery, specificity and potency. The properties of these analogs have been previously described extensively ([@B33]; [@B133]; [@B101]; [@B61]). Their stability in the presence of TRH-DE has seldom been directly tested or was tested against tissue homogenates that contain irrelevant peptidases. However, their stability in serum is a relatively good measure of their resistance to TRH-DE, since thyroliberinase is the main activity degrading TRH in serum. In this section, we describe TRH analogues that are resistant to TRH-DE.

TRH-like peptides in which the N-terminal Glp residue is replaced with a non-natural amino acid have promising pharmacological properties. Taltirelin (\[1-methyl-(S)-4,5-dihydroorotyl)\]-L-His-L-ProNH~2~) was synthesized by replacing the Glp residue of TRH with (S)-4,5, dihydroorotic acid ([@B203]). Taltirelin produces central nervous system (CNS) effects at about 100 times lower doses than TRH and has eight times longer duration of antagonistic action on pentobarbital-induced sleep than TRH ([@B236]; [@B237]; [@B103]). The differences in the activities of Taltirelin and TRH in the CNS have been attributed to the higher stability of Taltirelin in blood against thyroliberinase, and its higher lipophilicity than TRH that account for its increased penetration across the blood--brain barrier. Taltirelin resistance to hydrolysis by TRH-DE has been questioned, as Taltirelin was rapidly degraded in rat cerebral and pituitary homogenates ([@B107]; [@B105]), but it is likely that in these homogenates enzymes distinct from TRH-DE were actively degrading Taltirelin.

Montirelin (6-methyl-5-oxothiomorpholinyl-3-carbonyl-His-Pro-NH~2~, CG-3703) is a derivative of the Gln moiety of TRH, which is an efficient CNS-stimulating agent ([@B79]). This TRH analog readily penetrates into the brain after its systemic administration in rats ([@B83]) and inhibits specific Gln-\[3methyl-His\]-Pro-NH2 binding (Ki = 35 nM) to rat brain receptors as efficiently as TRH (Ki = 39.7 nM) ([@B219]). Montirelin exhibits high stability in the blood ([@B200]) and shows strong resistance to enzymatic degradation by pyroglutamyl aminopeptidase from brain or other related pyroglutamate aminopeptidases from liver and pituitary ([@B12]; [@B67]).

Azetirelin (N^α^-\[\[(5)-4-oxo2-azetidinyl\]carbonyl\]-His-Pro-NH~2~ dehydrate) has arousal actions 10--40 fold more potent and 8--36 times longer lasting than TRH ([@B234]). This longer duration of action is probably because Azetirelin has a longer half-life in dogs and humans than TRH. However, Azetirelin has low oral bioavailability ([@B182]) and methods to improve its absorption have been evaluated ([@B183]).

Posatirelin (L-6-ketopiperidine-2-carbonyl-L-leucyl-proline amide) is a neutral analog with improved CNS activity and with cholinergic, catecholaminergic and neurotrophic properties ([@B143]; [@B3]; [@B133]). Posatirelin has a stronger anticataleptic effect than TRH ([@B206]), and improves cognitive and motor disturbances in rats ([@B48]), while having poor influence on TSH release ([@B205]). Several human studies have also suggested beneficial effects in subjects with cognitive impairments ([@B38]; [@B145]). Posatirelin is stable in human and rabbit serum, while it is slowly degraded in rat and mouse plasma ([@B213]).

Rovatirelin (1-{N-\[(4S,5S)-(5-methyl-2-oxooxazolidin-4-yl)-carbonyl\]-3-(thiazol-4-yl)-L-alanyl}-(2R)-2-methylpyrrolidine trihydrate) has a higher affinity for TRH-R1 (Ki = 702 nM) than Taltirelin (Ki = 3,880 nM) but still lower than TRH (Ki = 128 nM) in cell membrane preparation from CHO-K1 cells overexpressing the human TRH receptor ([@B81]). Rovatirelin is resistant to thyroliberinase in rat plasma and also to TRH-DE in pituitary ([@B104]; [@B105]; [@B106]).

TRH-like peptides with simultaneous replacement of Glp by a panel of hetero ring-containing carboxylic acids and central histidine by 1-alkyl-L-histidines activate TRH-R2 with higher potencies than TRH-R1. One of these, with simultaneous substitution of Glp by pyrazine-2-carboxylic acid (2-Pyz) and central His with C~3~H~7~ (2-Pyz-~L~-His(1-alkyl)-~L~-Pro-NH~2~), exhibits high selectivity towards TRH-R2 but poor potency compared to TRH, high stability in rat blood plasma, antagonizes pentobarbital-induced sleeping time with a higher potency than TRH, and is devoid of adverse cardiovascular and CNS effects ([@B128]).

Another class of TRH derivative corresponds to those that have dual pharmacological activity, acting both as inhibitor of TRH-DE and as receptor agonist. Glp-Asn-Pro-AMC reversibly inhibits TRH-DE activity and binds preferentially to central TRH receptors ([@B96]). The replacement of the hydrophobic L-amino acid residues with their D-isomers in C-terminally extended analogs of Glp-Asn-Pro-NH~2~ led to Glp-Asn-Pro-D-Tyr-D-Trp-NH~2~ (named JAK4D), which is effective at producing and potentiating some central actions of TRH without evoking TSH release *in vivo*. This peptide has high plasma stability and combined potent inhibition of TRH-DE (Ki 151 nM) with high affinity binding to central TRH receptors (Ki 6.8 nM). In addition, JAK4D has a high ability to cross the blood--brain barrier and shows a clean preliminary toxicology profile ([@B185]; [@B98]).

To conclude, TRH analogs incorporating resistance to hydrolysis by TRH-DE and/or inhibition of TRH-DE activity associate with enhanced pharmacological activity, compared to TRH.

TRH-DE is Critical for the Extracellular Catabolism of TRH in the Central Nervous System {#s5}
========================================================================================

*Trhde* expression is detected at relatively late phases of brain development. TRH-DE activity appears in the male rat brain a few days before birth, and peaks at post-natal day 8 in hypothalamus and posterior cerebral cortex, while it decreases afterwards to adult values. The pattern differs in the olfactory bulb, two peaks of specific activity being observed at the 3th and 22nd day ([@B223]). *Trhde* expression is at least 10-fold higher in brain than in nine other organs of male or female Fisher 344 rats and this ratio is stable from 2 to 104 weeks ([@B244]) ([**Figure 2**](#f2){ref-type="fig"}). Thus, the brain is the region with the highest TRH-DE specific activity in adult animals ([@B222]; [@B118]).

![Distribution of *Trhde* expression in multiple rat organs. Heatmaps show the heterogeneous *Trhde* expression, predominant in the brain. Other differences can be observed along multiple developmental stages and between females **(A)** and males **(B)**. Data were refined from a database obtained from a transcriptomic profiling study in Fischer 344 rats ([@B244]; [@B75]).](fphar-11-00640-g002){#f2}

*Trhde* transcript levels and activity vary widely among brain regions, with highest values detected in cerebral cortex and hippocampus, as well as in cerebellar hemispheres, regions with limited *Trh* expression ([@B221]; [@B222]; [@B73]; [@B118]). In the adult rat brain, the map of *Trhde* transcript distribution is generally consistent with the proposal that it is expressed by neurons ([@B73]). This is congruent with evidence that TRH-DE activity is enriched in synaptosomes ([@B216]) and that in primary culture of E17 hypothalamic cells, neurons are the major cell type expressing TRH-DE activity ([@B36]). Furthermore, many rat cortical *Trhde* mRNA positive cells are *Slc17a7* mRNA positive (express vesicular glutamate transporter 1), and some *Gad* mRNA positive (express glutamic acid decarboxylase), which directly confirms that neurons express *Trhde* ([@B169]). Finally, single cell transcriptomic data of mouse CNS and peripheral nervous system ([@B249]) ([**Table 1**](#T1){ref-type="table"}) indicate that apart from many neuron types, the majority of non-neuronal cells have undetectable levels of *Trhde* mRNA.

###### 

Cells types along the mouse central and peripheral nervous system with the highest expression of *Trhde*, and relative expression of *Trhr* and *Trhr2*.

  Region                                                      Phenotype         *Trhde*   *Trhr*   *Trhr2*
  ----------------------------------------------------------- ----------------- --------- -------- ---------
  Hippocamposeptal projection, cortex/hippocampus             GABA/Sst          +++++     −        ++
  Nucleus of the solitary tract                               GABA/Gly/Ach      +++++     \+       −
  Myenteric plexus of small intestine                         Ach               ++++      −        −
  Subiculum/Cortex                                            Glu               ++++      \+       ++++
  Hippocampus CA3                                             Glu               +++       \+       −
  Lateral cortex layer 6: gustatory, barrel field, auditory   Glu               +++       −        −
  Superior Coliculus                                          Glu               ++        −        −
  Cortical pyramidal layer 4                                  Glu               ++        −        −
  Hippocampus interneurons                                    GABA              ++        −        −
  Interneuron-selective interneurons, cortex/hippocampus      GABA              ++        −        −
  Cortical pyramidal layer 6b                                 Glu               ++        −        −
  Cortical pyramidal layer 6                                  Glu               ++        −        −
  Entorhinal superficial layers                               Glu               ++        −        −
  Spinal cord, Dorsal cord lamina 2-5                         Glu               ++        −        −
  Inhibitory neurons, hindbrain                               GABA/Gly          ++        \+       ++
  Septal nucleus, Meissnert and diagonal band                 GABA/ACh          \+        \+       −
  Cerebral cortex                                             Glu               \+        −        ++
  Cortical pyramidal layer 6                                  Glu               \+                 ++
  Paragigantocellular reticular nucleus                       GABA/Gly          \+        ++       +++++
  Neuroblasts, olfactory bulb                                 Glu               \+        −        −
  Striatum/Amygdala                                           GABA/ACh          \+        \+       −
  Inhibitory neurons, midbrain                                GABA              \+        −        −
  Spinal cord, Dorsal cord lamina 2-5                         Glu               \+        −        −
  Lateral hypothalamus                                        Glu/TRH           \+        \+       −
  Piriform cortex                                             Glu               \+        +++++    −
  Septal nucleus                                              Glu               \+        −        −
  Inhibitory neurons, spinal cord                             GABA              \+        ++       −
  Basket and bistratified cells, cortex/hippocampus           GABA              \+        −        ++
  Cingulate/retrospenial area, layer 5                        Glu               \+        −        −
  Dorsal root ganglion                                        Glu               \+        −        −
  Sleep-active interneurons, cortex/hippocampus               GABA/Sst/NO/NPY   \+        −        −
  Interneuron-selective interneurons, cortex/hippocampus      GABA/VIP          \+        −        −
  Cortical pyramidal layer 5                                  Glu               \+        −        \+
  Cortical pyramidal layer 2/3                                Glu               \+        −        ++
  Piriform cortex, pyramidal neurons                          Glu               \+        −        −
  Interneuron-selective interneurons, hippocampus             GABA/VIP          \+        −        −
  Nucleus of the solitary tract                               Glu               \+        \+       −
  Hippocampus CA1                                             Glu               \+        −        −
  Cingulate/retrospenial area, layer 2                        Glu               \+        −        −
  Arcuate nucleus of the hypothalamus                         GABA/AgRP/NPY     \+        −        −
  Inner horizontal cell, olfactory bulb                       GABA              \+        −        \+
  Superior olivary complex                                    GABA/Gly          \+        −        −
  Pons                                                        GABA/NO           \+        −        −
  Ventromedial hypothalamus                                   Glu               \+        −        −
  Olfactory bulb                                              GABA              \+        −        −
  Anterior olfactory nucleus and ventral striatum             Glu               \+        −        −
  Superior Coliculus                                          GABA              \+        \+       −
  Granule neurons, cerebellum                                 Glu               \+        −        −
  Interneuron-selective interneurons, cortex/hippocampus      GABA/VIP/CRH      \+        −        −
  Pallidum                                                    GABA              \+        −        −
  A1-2 Noradrenergic cell groups                              Glu/Nor/PrlRH     \+        −        −
  Superior colliculus superficial grey layer                  GABA              \+        \+       −

Data obtained from single cell transcriptomic analysis ([@B249]). Expression level: - , undetected; + , very low; ++, low; +++, medium; ++++, high; +++++, very high. Ach, acetylcholine; AgRP, Agouti related peptide; CRH, corticotropin releasing hormone; Glu, Glutamate; Gly, glycine; NO, nitric oxide; Nor, norepinephrine; NPY, neuropeptide Y; PrlRH, prolactin releasing hormone; Sst, somatostatin; VIP, vasoactive intestinal peptide.

Many TRH neurons are glutamatergic ([@B249]). Although *Trhde* is expressed by multiple types of glutamatergic neurons, the regional distributions of *Trh* and *Trhde* mRNAs do not match ([@B74]); in contrast, destruction of serotonin (5HT) neurons of the raphe nucleus, where TRH colocalizes with 5HT, decreases TRH content, but not TRH-DE activity, in their projections to the spinal cord ([@B88]), suggesting *Trhde* is not co-expressed with *Trh* in this pathway. However, the single cell transcriptomic map of the mouse brain ([@B249]) shows that while many *Trhde* neurons do not express *Trh*, most *Trh* cell types do express low levels of *Trhde*, while two hypothalamic *Trh* cell types are clearly positive for *Trhde*. An independent single-cell mouse transcriptomic study showed that in the medial hypothalamus there are 5 predominant clusters of *Trh* neurons, one being clearly positive for *Trhde* ([@B22]).

Some TRH-DE neurons may be TRH-R1 or TRH-R2 positive, because the maps of the distribution of *Trhde*, *Trhr* and *Trhr2* mRNAs in the brain reveal a partial co-expression of *Trhde* and one of its receptors ([@B74]). Data at single cell level are consistent with coexpression in some neurons, but also indicate many mismatches ([@B249]). An example of a site of co-expression is the medial hypothalamus, where three of the five clusters of *Trhde* neurons do express *Trhr* ([@B22]). Furthermore, in the medial septum a large fraction of the *Trhde* cells does not express *Trhr* ([@B113]). We have no clues about the relationship between the subcellular localizations of TRH-DE and TRH-Rs in the cells that do express both *Trhde* and *Trhr* or *Trhr2*, in part because of the lack of TRH-DE antibodies suitable for immunocytochemistry. Existing data thus suggest no systematic association of TRH-DE with TRH receptors. What is thus the relevance of TRH-DE for TRH communication?

In brain slices, exogenous TRH is rapidly hydrolyzed, a major product being His-Pro-NH~2~, one of the two catabolites of TRH hydrolysis by TRH-DE *in vitro*, suggesting indeed that TRH-DE hydrolyzes TRH in the brain extracellular fluid ([@B121]). In brain slices, inhibition of TRH-DE activity with CPHNA increases TRH levels recovered in the extracellular medium, with a stronger effect in regions with higher TRH-DE activity ([@B28]). Glp-Asn-Pro-Tyr-Trp-Trp-AMC also enhanced recovery of TRH released from rat brain slices ([@B97]). Furthermore, perfusion of cortical slices with a TRH-DE inhibitor mimics the effect of TRH on the shape of action potentials generated by pyramidal neurons, suggesting that endogenous TRH released in the extracellular fluid is hydrolyzed by TRH-DE ([@B169]). Thus, extracellular turnover of TRH (either exogenous or endogenous) in brain slices is relatively rapid and occurs at least in part through hydrolysis by TRH-DE.

Besides these *in vitro* studies, there is indirect evidence that TRH may be hydrolyzed through TRH-DE activity in brain *in vivo*. If TRH is hydrolyzed by TRH-DE in the brain extracellular space, the reaction product His-Pro-NH~2~ could be degraded to His-Pro by dipeptidyl peptidase IV, a widely expressed ectoenzyme ([@B129]), and/or cyclize spontaneously to His-Pro-diketopiperazine (HPDKP), which may be metabolically stable and accumulate in the brain ([@B161]). HPDKP is indeed found in the brain and although diet may be an external source, part of HPDKP most likely comes from TRH hydrolysis since its concentration is reduced in the hypothalamus and cortex of TRH knockout mice ([@B231]).

A more direct evidence for the importance of TRH-DE in controlling the effects of TRH in the brain comes from a study on the effect of TRH on ethanol-induced narcosis. One of the pharmacological effects of TRH is its capacity to enhance alertness, and reverse narcosis, and one of the brain regions that mediate this last effect is the lateral septum. An intra-medial septum injection of the TRH-DE inhibitors pGlu-Asn-Pro-AMC, or Ψ-TRH which is not an agonist of TRH-R1, enhances the effect of exogenous TRH on the duration of ethanol-induced loss of righting reflex; the time of loss of the reflex is also decreased by the injection of Ψ-TRH alone ([@B113]). These data give further support to the proposal that TRH-DE regulates TRH turnover *in vivo*.

Although the relevance of TRH-DE for TRH inactivation in brain requires more extensive studies, it seems reasonable to conclude that its activity may at least in some anatomical contexts be present in neuron targets of TRH or adjacent neurons, and control the turnover of TRH, and thus duration and/or intensity of TRH effect. Although the primary products of TRH-DE activity (Glp and His-Pro-NH~2~) are inactive against TRH receptors, supporting an inactivation role, the product of His-Pro-NH~2~ cyclization, HPDKP, may mimic or oppose some TRH effects, making it possible to argue that TRH-DE bio-transforms TRH ([@B162]). At pharmacological doses HPDKP may be neuroprotective and improve glucose metabolism in obese and/or diabetic animals ([@B131]). However, the physiological relevance of TRH biotransformation to HPDKP in brain is currently unknown. Thus, it seems pertinent to conclude that a major function of TRH-DE is TRH inactivation in the brain. In contrast, it remains to be determined whether Gln-Phe-Pro-NH~2~ and Gln-Tyr-Pro-NH~2~ actions are indeed terminated by TRH-DE activity *in vivo*.

Potential Therapeutic Targeting of TRH-DE in the CNS {#s6}
====================================================

This section covers some of the major pharmacological properties of TRH, and of the two TRH-like peptides that are potential *in vivo* substrates of TRH-DE in the CNS, to illustrate the contexts in which TRH-DE targeting may be considered therapeutically beneficial.

Except for TRH neurons controlling the HPT axis, few experimental studies have addressed the *in vivo* physiological role of other TRH neurons. This is because of the absence of useful TRH-R antagonists *in vivo*, of the difficulty to manipulate the activity of specific TRH subtypes, and to limited information about the projections of various TRH neuron types. Some studies used strategies that correlate behavior with markers of TRH neuron activity, such as evaluation of the expression of *Trh* or cFOS, or region-specific manipulation of *Trh* expression. Along with tracing experiments, this research laid the ground to insert some TRH neurons in physiological contexts. Many studies have rather evaluated the impact of TRH or analogues on behavior and/or biochemical markers of neuronal activity. Peripheral or central (intracerebroventricular or nucleus-specific) administration of TRH or analogues produces in laboratory animals multiple behavioral changes, besides activation of the HPT axis. The mechanisms of TRH action are not fully understood, although advances have been made to characterize the electrophysiological/biochemical effects of TRH, and to identify target cells and circuits involved. Initial results led to early attempts to use TRH and analogues with improved stability, agonist potency and/or brain accessibility for experimental treatment of psychiatric or neurological diseases. A comprehensive analysis of TRH effects is beyond the scope of this review; the reader is referred to excellent reviews ([@B99]; [@B79]; [@B61]; [@B41]; [@B57]). As for other receptors, TRH or analogue action is not only limited by access and stability, but also by ligand-induced desensitization and down regulation ([@B201]; [@B77]). Reduced TRH receptor binding and behavioral tolerance is observed after repeated administration of TRH ([@B142]; [@B195]), a fact that stresses one of the limits of the therapeutic use of any analogue. We will restrict the following paragraphs to some well-established effects of TRH or analogues, and whenever knowledge permits to discuss the targeting of TRH-DE.

TRH administration acutely increases arousal and locomotion; these effects are reproduced by direct injection of TRH into nucleus accumbens and septum ([@B79]). Other central regions are likely involved; for example, TRH increases the activity of lateral hypothalamus orexin neurons, which project to several areas involved in arousal ([@B64]; [@B71]). TRH-induced dopamine release has been observed in different paradigms and was proposed to be involved in TRH-induced motor activity ([@B91]; [@B238]). The effect of TRH on arousal is also related with TRH-induced awakening from ethanol narcosis and coincides with the stimulatory effect of acute ethanol administration on *Trh* mRNA levels, accompanied with decreased *Trhde* mRNA levels and TRH-DE activity, and TRH tissue content, suggesting increased release of TRH in nucleus accumbens ([@B43]). In the septum, there is evidence that inhibition of TRH-DE activity promotes arousal from ethanol narcosis ([@B113]). Contrary to TRH, Gln-Phe-Pro-NH2 and Gln-Tyr-Pro-NH2 are not analeptic ([@B76]). Amplification of TRH action on arousal by TRH-DE inhibition may be therapeutically useful in niche applications.

TRH or analogue administration has generally a strong anorexic effect. The anorexic effect of TRH is probably mediated through multiple target regions; one of them is the nucleus accumbens, where TRH may interact with dopaminergic communication ([@B164]). Other regions potentially involved in the anorexic effect of TRH are various hypothalamic nuclei, such as the tuberomammillary nucleus, where TRH containing axons innervate histamine neurons ([@B65]; [@B178]), or the perifornical area/bed nucleus of stria terminalis region, from where TRH neurons may control the activity of proopiomelanocortin neurons of the arcuate nucleus ([@B144]). However, it was also noted that TRH injection into the brainstem promotes food intake through TRH-R1 activation ([@B4]), suggesting that control of food intake through TRH manipulation may require the optimization of the access route. There is not yet any experimental evidence showing that TRH-DE may regulate the anorexic (or orexigenic) effect of TRH.

TRH improves cognitive function ([@B15]). TRH analogs administered to animals prevent the memory impairment caused by chronic ethanol administration or brain lesions ([@B15]; [@B61]; [@B41]; [@B128]). *In vivo*, TRH, or some analogs, activate the septo-hippocampal and basalis cortical cholinergic systems, eliciting acetylcholine release onto the hippocampus and cortex and restore cognitive deficits of animals with lesions in the medial septum ([@B82]; [@B15]; [@B79]; [@B163]; [@B41]). The TRH analogue 2-Pyz-~L~-His (1-alkyl)-~L~-Pro-NH~2~, which exhibits high selectivity towards TRH-R2, and is more stable in rat blood plasma than TRH, possesses cognitive-enhancing activity when administered intravenously in the scopolamine-induced cognition impairment mice model, evaluated with the Morris water maze and the passive avoidance tests ([@B128]).

The hippocampus is critical in learning and memory. TRH immunoreactivity is detected in pyramidal and granular layers of CA1 and CA3, and in ventral dentate gyrus coincident with TRH binding ([@B70]; [@B192]) and with expression of *Trhr* ([@B21]; [@B74]). In support of the relevance of hippocampal TRH communication in learning, the status of TRH transmission is modified in the hippocampus of rats trained for 5 days in the water maze. TRH release is reduced, whereas expression of *Trh* and *Trhr* is upregulated in CA3, supporting plastic changes induced by the process of learning ([@B2]). TRH produces a time-dependent biphasic effect on NMDA receptor responses ([@B248]), whereas it increases the excitability of GABA interneurons ([@B45]) in the hippocampus. Interestingly, pyramidal cells of the Ammon\'s horn express *Trhde* mRNA in abundance ([@B73]); *Trhde* may be expressed on the cell body and/or dendrites of the CA neurons. Blockade of NMDA receptors by MK801 decreases relatively rapidly TRH-DE activity in hippocampal slices, while blockade of AMPA or GABA-A receptors does not ([@B168]). Additional cognitive effects of TRH may be direct onto cerebral cortex, where *Trhde* mRNA expression is also high ([@B73]) and TRH-DE regulates TRH action on pyramidal neurons action potential shape ([@B169]). Thus, cognitive actions of TRH may be amplified by inhibition of TRH-DE activity.

Several reports show that endogenous or exogenous TRH is an anticonvulsant ([@B108]; [@B184]; [@B179]). In man, TRH is efficient for treatment of West syndrome, Lennox-Gastaut syndrome, and early infantile epileptic encephalopathy ([@B209]). The electrical subthreshold stimulation produced during kindling in the amygdala or the hippocampus increases *Trh* expression or TRH content ([@B173]; [@B109]; [@B42]). Amygdala kindling increases *Trh* expression, but decreases that of *Trhr*, *Trhr2*, and *Trhde* in amygdala, and hippocampus, while only that of *Trhr2* and *Trhde* in frontal cortex ([@B44]). TRH content increases as kindling progresses whereas the activity of TRH-DE increases in the initial stages and decreases once kindling is established ([@B42]). Decreased *Trhde* expression may facilitate the protective effects of TRH. These data suggest that inhibition of TRH-DE may be protective in some forms of epilepsy.

The peripheral or central administration of TRH produces an anxiolytic effect in several animal tests ([@B225]; [@B215]; [@B68]). There is evidence that endogenous TRH can perform a similar function. Thus, in animals subjected to the defensive burying test, there is a specific inhibition of TRH release and *Trh* mRNA levels in amygdala but not in other limbic areas ([@B68]). Furthermore, amygdalar *Trh* expression and anxiety behavior are inversely correlated in the elevated plus maze and in the open field test ([@B69]). In adult male rats, exposure to an open field test during the inactive phase increases *Trh* expression in the cortical nucleus of the amygdala, an area involved in processing fear stimuli ([@B68]). *Trhr* KO mice are more anxious than wild type relatives ([@B250]) while those deficient in *Trhr2* exhibit reduced anxiety ([@B202]). It is warranted to test the status of *Trhde* KO mice.

Experimental evidence for an antidepressant effect of TRH in animal models and humans is controversial, although *Trhr2*-deficient mice are euthyroid and exhibit a depressive behavior ([@B202]). As an example of controversy, the injection of TRH into rats decreases the immobility time in the Porsolt test ([@B47]) whereas the injection of Taltirelin into the amygdala increases the immobility time in chronic-stress-induced depressed mice. In the depressed mice, *Trh* and *Trhr* expression in the basolateral amygdala is increased after 14 days of 2 h of daily restraint ([@B32]). This result seems to contradict the reported anxiolytic effect of TRH. Species and strain differences in stress responses and the previous stress history of the animal ([@B89]) may explain some of these discrepant results. Finally, Gln-Tyr-Pro-NH~2~ is active in the Porsolt Swim Test ([@B152]). Since mood stabilizing valproate acutely enhances, among other TRH-like peptides, Gln-Tyr-Pro-NH~2~ concentration in brain regions and most notably in pyriform cortex ([@B151]), it will be relevant to take Gln-Tyr-Pro-NH~2~ into account if TRH-DE is targeted for an anti-depressant effect.

Several neurologic disorders improve with treatment with TRH and some of its stable analogs. This has been shown for scopolamine-induced memory loss, prolonged impaired consciousness ([@B79]; [@B128]), and neuronal death occurring after a transient ischemic attack (TIA) ([@B194]). In rats, *Trh* expression increases in peri-ischemic tissue, while that of *Trhde* drops drastically. The response is independent of age of induction of TIA, and post-ischemia time. This may be a TRH protective effect, amplified by *Trhde* down regulation ([@B19]). Neuroprotective actions of TRH analogs include protection against neuronal injury induced by excitotoxicity and oxidative stress, and inflammation ([@B61]; [@B41]; [@B57]). In the spinal cord, TRH may be involved in motor activity control and pain modulation; its administration promotes the recovery from acute spinal cord injury and has been used clinically with promising results ([@B53]). Taltirelin, which is degradation resistant, has been accepted in the treatment of spinocerebellar degeneration (SCD) ([@B102]; [@B103]). Taltirelin has anti-ataxic and neuroprotective actions ([@B220]; [@B138]; [@B224]). Finally, JAK4D elicits large neuroprotective effects in neurodegenerative animal models. Systemic administration of JAK4D reduces cognitive deficits in a kainate (KA)-induced rat model of neurodegeneration, protects against free radical release and neuronal damage evoked by KA in rat, and reduces motor decline and lumbar spinal cord neuronal loss in a transgenic Amyotrophic Lateral Sclerosis mice model ([@B98]). These data point to the importance of targeting TRH-DE to improve treatment of neurodegenerative diseases with TRH derivatives.

TRH analogs resistant to degradation by TRH-DE are promising for treating some neurological disorders. However, autonomic effects of these analogs need to be considered. Central TRH application has effects on the respiratory, cardiac and gastric systems. Most of these actions are due to targets of the TRH neurons present in brain stem. TRH is synthesized in raphé pallidus, obscurus, and para-pyramidal neurons that project to sympathetic preganglionic neurons of the intermediolateral (IML) cell column of the spinal cord and to vagal motor neurons located in the dorsal vagal complex ([@B207]). Some of TRH neurons that project to the IML use serotonin and substance P as co-transmitters; depending on the complement of receptors in target neurons, TRH participates in several aspects of respiratory network control ([@B78]).

In the vagal complex TRH activates neurons of the dorsal motor nucleus of the vagus that project to visceral organs such as pancreas regulating insulin secretion ([@B240]), or as stomach, stimulating gastric secretion ([@B208]). TRH-TRH-R1 signaling in brain stem, or TRH administered in low doses, have protective action against damaging agents in the gastric mucosa, whereas this is not the case in high doses as injections into the cisterna magna induce a dose-related activation of gastric vagal efferent discharges in rats. TRH applied in the hindbrain modulates gastric secretion and motility, blood pressure, hepatic blood flow, stimulates brown adipose tissue thermogenesis and respiratory output ([@B207]; [@B80]; [@B241]; [@B158]). Although TRH-DE activity is lower in the brain stem than in other regions of the brain ([@B222]), the potential to alter autonomic functions if TRH-DE is affected cannot be underestimated.

In conclusion, at CNS level, many TRH effects, and some Gln-Phe-Pro-NH2 and Gln-Tyr-Pro-NH2 actions, may have a therapeutic potential (i.e. antiepilepsy, anxiolysis, improvement of learning, neuroprotection). The presence of TRH-DE in many of the sites of action of TRH suggests that inhibition of TRH-DE activity should increase the action of endogenous TRH. This may produce results that are better suited than those sought with TRH analogues.

TRH-DE and the Thyroid Axis {#s7}
===========================

This topic has been recently reviewed ([@B170]) and will only be briefly discussed here. Although a large part of CNS *Trhde* is expressed in neurons, a few years ago it was discovered that *Trhde* is expressed in tanycytes of the hypothalamus, a glial cell type localized at the base and ventrolateral walls of the third ventricle of the hypothalamus ([@B176]). All sub-types of tanycytes express *Trhde*; the β2 tanycytes, which send cytoplasmic extensions into the external layer of the median eminence where they are close to TRH terminals of the parvocellular TRHergic neurons of the PVN, in proximity of the portal capillaries that transport TRH to the anterior pituitary have the highest expression of *Trhde* ([@B176]). In median eminence explants, TRH-DE inhibition enhances TRH recovered from the incubation medium, suggesting that the enzyme actively hydrolyses TRH in the median eminence extracellular space ([@B176]). Thus, after release TRH may be partially hydrolyzed by TRH-DE before entry into the portal vessels. A physiological consequence would be that the amount of TRH reaching the anterior pituitary would not only depend on the activity of the TRH neurons, but also on median eminence TRH-DE activity, which would regulate the intensity of TRH-induced TSH secretion according to clues detected at median eminence level. Consistent with this idea, it was shown that although the intraperitoneal injection of HcPI in control animals does not change serum concentration of TSH, it does increase it in cold stressed animals ([@B176]). Although HcPI inhibits TRH-DE activity inside the blood--brain barrier, as well in the anterior pituitary and serum, *Trhde* expression is not detected in thyrotropes, and inhibition of TRH-DE expression or activity does not enhance TRH-induced TSH release ([@B10]; [@B37]); this evidence strongly suggests that anterior pituitary TRH-DE is not critical for the control of TSH release. Finally, the role of the serum enzyme, that is produced by the liver ([@B187]) cannot be discarded, since this isoform likely circulates through the portal vessels. Although a definitive demonstration for control of TRH entry into the portal capillaries by tanycyte TRH-DE is required, evidence about regulation of TRH-DE activity is also consistent with this proposal.

A major mode of control of the activity of the HPT axis is negative feedback at various levels, including inhibition of *Trh* mRNA synthesis in the hypophysiotropic neurons of the PVN ([@B54]). At the level of the tanycytes, *Trhde* expression and activity are rapidly (in a few hours) stimulated by peripheral injection of T4, thus putatively contributing to the negative feedback ([@B176]). The effect of T4 on *Trhde* depends on the local conversion of T4 to T3 by deiodinase 2 *(Dio2*) also expressed in tanycytes ([@B123]). The mechanism by which TH induces *Trhde* expression is not known; thyroid hormone response elements have not been detected in the vicinity of the putative transcription initiation of *Trhde* ([**Figure 1**](#f1){ref-type="fig"}), although many genes regulated by TH do not contain them ([@B30]).

The HPT axis is regulated by energy balance ([@B54]; [@B90]). Apart from down regulation of TRH neurons activity, a prolonged fast enhances *Dio2* and *Trhde* expression and activity in the male rat median eminence ([@B46]; [@B114]). The transient induction of *Trhde* expression may contribute to prolong the downward adjustment of the HPT axis, along with an increase in thyroliberinase activity, in spite of a partial reactivation of *Trh* synthesis by the PVN at 72 h fasting ([@B114]). Other data show that diet-induced obesity (with unsaturated fat) enhances median eminence *Trhde* expression in male rats ([@B85]), suggesting that the relationship between energy balance and activity of TRH-DE is complex. Finally, *Trhde* expression in the median eminence is programed by neonatal stress, along with other aspects of HPT axis function ([@B84]). It is thus evident that long-term events shape median eminence TRH-DE activity.

In these models, there are few clues about the immediate regulators of *Trhde* expression/activity, and it has not been shown that *Trhde* adjustments are critical for HPT axis activity. The local thyroid status is probably involved ([@B114]) and besides hormonal signals, tanycytes are responsive to neuronal inputs. Recently it was shown that the release of TRH in the median eminence activates the TRH-R1 receptor on the surface of tanycytes, resulting in two rapid events: an increase of the surface of tanycyte end-feets covering the portal capillaries, and an increase in TRH-DE activity in the median eminence, both of which may reduce TRH access to the capillary bed. Furthermore, a long term (days) blockade of Gq transduction decreased TRH-DE activity. Thus, the firing of TRH neurons likely regulates TRH-DE activity and localization. This coordinated mechanism may help to shape the pulses of TRH that reach the anterior pituitary ([@B122]).

An intriguing question is the relevance of TRH-like peptides sensitive to hydrolysis by TRH-DE in the control of the HPT axis. Gln-Phe-Pro-NH~2~ is released from hypothalamic slices ([@B121]), Gln-Phe-Pro-NH~2,~ as well as TRH, is detected in rat thyroid ([@B166]; [@B198]) and Gln-Phe-Pro-NH~2~ enhances serum T3 concentration ([@B35]). Thus, median eminence and thyroid gland may be sites where the functional relationship between Gln-Phe-Pro-NH~2~ and TRH-DE warrants further investigation.

Targeting Median Eminence TRH-DE to Control Thyroid Status? {#s8}
===========================================================

Thyroid diseases are very common and a major one is sub-clinical or clinical hypothyroidism, which is mainly treated with T4 (and T3). Although this therapeutic option is successful, it is not perfect and there is room for improvement. Among the major problems of the therapeutic use of TH is the risk of producing unattended hyperthyroidism and thus cardiovascular or skeletal consequences. These problems have led to significant avenues of research, to limit unintended effects. One of these approaches has been the development of specific agonists of TH receptor β ([@B174]). Another focus has been on the development of thyroid hormone-peptide complexes, to direct TH to the tissues that express the peptide receptor ([@B56]).

Peripheral inhibition of peptidase activity has been quite successful in various contexts (hypertension, type 2 diabetes). Although requiring confirmatory experiments, the weight of evidence strongly suggests that in rats median eminence TRH-DE activity controls the output of TRH and thus TSH secretion, at least during bouts of TRH neurons activity. This suggests that inhibition of this enzyme may transiently increase TRH-induced TSH secretion, enhancing the hypothalamic signal that promotes TSH secretion in conditions of insufficient drive. Because β2 tanycyte TRH-DE activity is outside the blood brain barrier, it should be possible to target this compartment and enhance the extracellular concentration of TRH in the portal vessels, without affecting TRH communication in the rest of the CNS. Furthermore, the narrow specificity of TRH-DE should facilitate the development of agents that have no impact on other peptides turnover. The final purpose of this manipulation would be to enhance thyroid hormone secretion without changing the natural pattern of control of the HPT axis and to produce self-regulated and small effects on TH concentration, reducing cardiovascular and bone effects.

Various milestones should be reached to target peripheral TRH-DE activity to improve thyroid status in hypothyroidism. One is to characterize the long-term impact of TRH-DE inhibition on HPT axis parameters, since the axis can self-regulate efficiently; for example, the long-term ablation of tanycytes does not change serum TSH concentration ([@B243]). Another consideration is that changes in serum TSH concentration may have non thyroidal effects. Likewise, prolactin secretion would have to be monitored, to exclude alteration of this critical hormone. Finally, the distribution and role of TRH-DE activity in the periphery requires clarification.

TRH-DE and Prolactin Secretion {#s9}
==============================

In mammals, apart from the negative control of prolactin secretion by hypothalamic tuberoinfundibular dopamine neurons, hypothalamic prolactin releasing factors are also important ([@B66]). TRH is not only a thyrotropin releasing factor but also a prolactin releasing factor. TRH is necessary to maintain maximal prolactin output in lactating mice ([@B233]). In primary cultures of female rat anterior pituitary cells, *Trhde* expression is detected in some lactotropes, and inhibition of TRH-DE expression or activity enhances TRH-induced prolactin secretion ([@B10]; [@B37]). If the importance of *Trhde* for the control of prolactin secretion, which is contingent on many factors, is confirmed in relevant *in vivo* models, inhibition of anterior pituitary TRH-DE activity might increase prolactin secretion.

TRH-DE in Peripheral Tissues {#s10}
============================

Although targeting of CNS and/or median eminence/pituitary TRH-DE activity has experimental support, a much less understood aspect is the function of *Trhde* expressed in the periphery. This must be fully assessed for establishing the safety profile of the peripheral inhibition of TRH-DE activity or expression. [**Figures 2**](#f2){ref-type="fig"} and [**3**](#f3){ref-type="fig"} illustrate that although the brain is a major source of *Trhde* expression, developmentally regulated expression of *Trhde* is also detected in multiple rat tissues, of both sexes. However, it should be noted that in rats and rabbits, the peripheral tissues have low levels of TRH-DE activity ([@B222]). Human transcriptomic data indicate baseline expression of *Trhde* in various peripheral organs, being more abundant in kidney, spleen, ovaries, uterus, adipose tissue, small intestine Peyer\'s patch, duodenum, pancreas, and lung, and lower in colon, prostate, stomach and testis. In these tissues, *Trhde* expression is detected in adults. For kidney, lung, stomach and testis, *Trhde* expression has also been reported at early stages of embryonic development ("ensembl.org: TRHDE---ENSG00000072657," n.d. and "bgee.org: TRH-DE---ENSG00000072657") ([**Figure 3**](#f3){ref-type="fig"}). We review below the state of knowledge about TRH-DE in the best-studied tissues.

![Potential sites of targeting of TRH-DE in rats and humans. *Trhde* is mainly expressed in a few major organs; in rats, gene expression is higher in brain followed by lung, liver and uterus; in humans, major sites of expression are cerebellum and pancreas. Panel **(A)** illustrates tissue *Trhde* expression distribution in rat (log2 FPKM, fragments per kilobase of transcript per million mapped reads) based on the database of the rat body map available from <http://pgx.fudan.edu.cn/ratbodymap/index.html> ([@B244]); some of the brain regions which express medium (i.e. hypothalamus) to high mRNA levels are also indicated ([@B73]). Panel **(B)** illustrates tissue *Trhde* expression distribution in humans based on the Human Protein Atlas available from <http://www.proteinatlas.org> ([@B218]). Colors on organ/tissue names represent expression levels of *Trhde*. Information regarding sex and age of the donor, can be found at <http://www.proteinatlas.org/about/cellines>. Figure was created with Biorender.com.](fphar-11-00640-g003){#f3}

Thyroliberinase is a liver specific isoform of TRH-DE ([@B187]) that is secreted into the general circulation. It is the only enzyme that degrades TRH in rat serum ([@B58]). Its role is puzzling; it probably reaches the hypothalamic-pituitary portal vessels, but its specific relevance for anterior pituitary control is untested. Thyroliberinase may also reduce the buildup of TRH concentration in the peripheral tissues where TRH may act as a paracrine effector ([@B136]). Finally, it should contribute significantly to the limited efficiency of the parenteral injection of TRH, being an interesting target to enhance the efficacy of parenteral TRH analogues.

One of the peripheral tissues in which TRH presence was noticed early is the rat pancreas, where it is concentrated in the islets of Langerhans ([@B125]). A transient prenatal expression of *Trh* is detected in pancreatic β-cells, which coincides with development of insulin secretory activity ([@B239]; [@B8]; [@B199]). In rodents, *Trhr* is expressed in the pancreas, including in β-cells ([@B232]; [@B120]); a potential effect of TRH-TRH-R1 is the promotion of programmed cell death during development ([@B137]). *Trh* KO mice have an increased glycemia, which may be the result of reduced secretion of insulin in response to high glucose concentration ([@B230]). On the other hand, *Trhr* KO mice are hypothyroid and hyperglycemic ([@B250]), while *Trhr2* KO mice are euthyroid and normoglycemic ([@B202]). Gln-Phe-Pro-NH2 is detected in pancreas, where it attenuates TRH effect on insulin secretion in perifused islets ([@B110]). Although pancreatic *Trhde* expression is significant in human ([**Figure 3**](#f3){ref-type="fig"}), there is no evidence for TRH-DE activity in developing or adult rat ([@B223]). *Trhde* KO mice are normoglycemic ([@B210]). The relevance of TRH-DE in human pancreatic function requires an urgent investigation; is expression leading to TRH-DE activity, or to non-active isoforms?

*Trh*, and *Trhr* are expressed in the heart, in fibroblasts and in cardiomyocytes ([@B23]; [@B193]); TRH, as well as Gln-Phe-Pro-NH~2~ and Gln-Tyr-Pro-NH~2~, are detected in heart tissue, where values vary along the circadian cycle ([@B150]). Various evidences suggest that heart TRH might be relevant in cardiovascular disease. TRH induces hypertrophic and fibrotic markers in heart cells ([@B190]). Overexpression of *Trh* in left ventricular cells promotes heart hypertrophy in rats ([@B87]). Spontaneously hypertensive rats overexpress *Trh* in the left ventricle, and reduction of *Trh* expression inhibits fibrosis and cardiomyocyte enlargement ([@B189]). Furthermore, angiotensin II--induced heart hypertrophy depends on *Trh* expression ([@B154]). Thus, TRH may have a substantial role in cardiac hypertrophy. *Trhde* is expressed in the heart of Fischer-344 male and female rats, with noticeable developmental increases ([**Figure 2**](#f2){ref-type="fig"}) ([@B244]). In the human heart, *Trhde* transcripts can be detected at 10 weeks ([@B204]). It will be important to clarify whether TRH-DE activity is present in heart and controls local TRH and/or Gln-Phe-Pro-NH~2~ and Gln-Tyr-Pro-NH~2~ actions.

TRH-like immunoreactivity is detected in various organs of the digestive system ([@B116]). TRH levels are high in gastric juice and mucosa ([@B139]). In the digestive system, while TRH-R1 presence in the stomach is scarce (Nishio et al., 1990), TRH-R1 has been detected by immunohistochemistry in the small intestine ([@B132]), where TRH excites submucus neurons and enhances heat shock protein 60 expression ([@B247]; [@B181]). One subtype of cholinergic neuron, in the myenteric plexus of the mouse small intestine, is characterized by a very high expression of *Trhde* ([@B249]) ([**Table 1**](#T1){ref-type="table"}), but these neurons, which may receive vagal afferents, do not express *Trhr* or *Trhr2*. In this system, TRH-DE may inactivate TRH produced and released locally. However, as for the heart, there is yet no evidence that TRH-DE activity is present in the intestinal mucosa. Because of the high relative expression of *Trhde* in neurons of the enteric system, potential adverse effects of TRH-DE manipulation should be considered. In humans, intestinal *Trhde* expression initiates around 10--20 weeks of age ([@B204]), being significant in adults. An accumulation of neuropeptides, including TRH, in the lumen of the colon of patients with inflammatory bowel disease ([@B235]) is noticeable; animal models of the disease might shed light about TRH-DE role in this pathology, if any.

TRH has significant effects over the function of immune system, some of which dependent on pituitary control ([@B92]). Hypophysiotropic TRH neurons are involved in inflammation responses dependent and independent of T-cell activation. LPS administration doesn\'t induce T-cell activation and is linked with an initial reduction of *Trh* expression in the PVN ([@B92]). However, T-cell dependent inflammation induces the opposite, with the response dependent on hypophysiotropic TRH neurons and prolactin secretion from the pituitary ([@B155]). Although the site of TRH production acting directly on immune cells is unknown, TRH-R1 can be detected in lymphoid tissues, including the thymus ([@B134]) and bone marrow ([@B126]). Administration of TRH in rats increases the proliferation of cells of the thymus ([@B148]) and protects against its involution and reduction of the count of lymphocytes in peripheral blood, induced by lateral hypothalamus lesion ([@B117]). TRH may thus be of therapeutic value in diseases dependent on immune system activation. Administration of TRH protects against pathogens such as encephalomyelitis virus ([@B156]), and candidiasis ([@B18]). Transcriptomic analysis reveals that *Trhde* is expressed in thymus, with a significant drop of expression in aging rats ([**Figure 2**](#f2){ref-type="fig"}) ([@B244]). Although TRH-DE activity and function have not been determined in lymphoid organs, TRH-DE inhibitors could be interesting alternatives to TRH treatment in inflammatory diseases.

In the reproductive system, Leydig cells express both *Trh* and *Trhr* ([@B150]). Repeated administration of TRH counters aging-induced alteration of rat testicular structure and function ([@B157]). Gln-Phe-Pro-NH~2~ is also expressed by the prostate and detected in seminal fluid ([@B17]; [@B100]; [@B63]); however, its local effect is unknown. In females, TRH increases the contractility of urethral and vaginal muscle ([@B245]) and Gln-Phe-Pro-NH2 is detected in the mammary gland ([@B62]). Since low levels of expression of *Trhde* occur in various reproductive organs ([**Figure 3**](#f3){ref-type="fig"}), its relevance for TRH or Gln-Phe-Pro-NH~2~ actions may not be important but should nevertheless be investigated.

In conclusion, there is little evidence that, apart from pituitary and liver, other peripheral tissues which express *Trhde* give rise to significant TRH-DE activity. It remains possible that in some tissues expression might be mainly attributed to the mRNA coding for the truncated version of TRH-DE ([@B31]) and that TRH-DE\* is not only a dominant negative isoform of TRH-DE but is also a non-catalytic protein. However, *Trhde* KO mice do not show any obvious problem in standard conditions, except for a small decrease of body weight ([@B210]). Finally, it will be critical to clarify the extent of TRH-DE activity in human tissues.

Conclusions and Challenges {#s11}
==========================

With the available information of the wide distribution of TRH receptors, and the multiple functions TRH displays, the pharmacological use of agonists of the TRH-R1 receptors that resist degradation by TRH-DE might impact on many functions.

Albeit alternatives are not completely excluded yet, it appears that hydrolysis by the TRH degrading ectoenzyme in the serum and the extracellular space of the brain, including the median eminence, is a critical pathway for TRH inactivation. The relevance of this enzyme for Gln-Phe-Pro-NH~2~ and Gln-Tyr-Pro-NH~2~ inactivation remains to be investigated. Since most central pharmacological effects of peptidase resistant analogues of TRH are beneficial in rodents, and there is some consistent evidence in humans, targeting central TRH-DE with specific inhibitors may have significant advantages over TRH agonists in some central diseases, in particular to produce more focused effects according to the natural activity of the TRH neurons. On the other hand, the limited span of the distribution of TRH-DE activity in the periphery opens the possibility that inhibition of median eminence TRH-DE activity may be an interesting target for treatment of hypothyroidism and may have few non-intended targets, if a compound that does not pass the blood-brain barrier is chosen. However, it will be necessary to understand the full extent of the distribution of peripheral TRH-DE activity and function in humans before this idea proceeds further.

Targeting the inactivation process in the brain will increase ligand concentration in the synaptic space and increase TRH effect, alike the mechanism of action of drugs that inhibit neurotransmitter uptake. However, an intrinsic problem lies on the stringent specificity of TRH-DE for the TRH structure. Thus, it is not surprising that some of the TRH-DE inhibitors function also as TRH-R agonists ([@B185]) and may thus promote receptor down regulation or, undesirable side effects. For example, even for a more stable analog of TRH as Taltirelin, hyperprolactinemia is induced ([@B93]). Even if the analog does not produce endocrine effects in humans, other peripheral effects such as induction of gastric erosion and hypermotility of the intestine may occur. The challenge to design a specific inhibitor to TRH-DE not recognized by TRH-R1 has been overcome with Ψ-TRH design, although better chemistries and affinities are required. In theory, this should be possible, as has been done for other proteases ([@B147]; [@B217]; [@B111]).

Even if better inhibitors are found, unknowns remain. Are Gln-Phe-Pro-NH~2~ and Gln-Tyr-Pro-NH~2~ physiologically relevant substrates of TRH-DE? Does inhibition of TRH-DE activity has concrete effects in preclinical models? These, and other milestones, need to be passed to determine if manipulation of TRH-DE expression or activity has therapeutic potential.
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